Mirae Asset Global Investments Portfolio holdings
AUM
$28.7B
1-Year Return
20.96%
This Quarter Return
+4.4%
1 Year Return
+20.96%
3 Year Return
+114.88%
5 Year Return
+202.83%
10 Year Return
+496.23%
AUM
$24.6B
AUM Growth
+$2.03B
(+9%)
Cap. Flow
+$1.25B
Cap. Flow
% of AUM
5.09%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
1,702
New
151
Increased
731
Reduced
674
Closed
110
Top Buys
| 1 |
Vanguard S&P 500 ETF
VOO
|
$168M |
| 2 |
Apple
AAPL
|
$71.3M |
| 3 |
Microsoft
MSFT
|
$57.4M |
| 4 |
HDFC Bank
HDB
|
$44.6M |
| 5 |
Schwab US Dividend Equity ETF
SCHD
|
$40.5M |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
$83.3M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$81.2M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
$43.3M |
| 4 |
Broadcom
AVGO
|
$42.7M |
| 5 |
Advanced Micro Devices
AMD
|
$37.7M |
Sector Composition
| 1 | Technology | 33.15% |
| 2 | Consumer Discretionary | 10.25% |
| 3 | Communication Services | 8.94% |
| 4 | Healthcare | 6.61% |
| 5 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1526
C4 Therapeutics
CCCC
$199M
| $8.91K | ﹤0.01% |
+2,352
| New | +$8.91K |
|
|
ITOS
1527
DELISTED
iTeos Therapeutics
ITOS
| $8.91K | ﹤0.01% |
1,217
-104
| -8% | -$761 |
|
1528
Amylyx Pharmaceuticals
AMLX
$877M
| $8.84K | ﹤0.01% |
2,284
-178
| -7% | -$689 |
|
|
ARTV
1529
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$79.1M
| $8.61K | ﹤0.01% |
+809
| New | +$8.61K |
|
1530
Flywire
FLYW
$1.57B
| $8.58K | ﹤0.01% |
416
-84
| -17% | -$1.73K |
|
1531
4D Molecular Therapeutics
FDMT
$331M
| $8.55K | ﹤0.01% |
1,540
-340
| -18% | -$1.89K |
|
1532
Larimar Therapeutics
LRMR
$342M
| $8.42K | ﹤0.01% |
+2,126
| New | +$8.42K |
|
1533
StoneCo
STNE
$4.54B
| $7.79K | ﹤0.01% |
977
-198
| -17% | -$1.58K |
|
1534
Lexeo Therapeutics
LXEO
$283M
| $7.47K | ﹤0.01% |
+1,102
| New | +$7.47K |
|
|
IGMS
1535
DELISTED
IGM Biosciences
IGMS
| $7.24K | ﹤0.01% |
+1,136
| New | +$7.24K |
|
1536
Inhibrx
INBX
$401M
| $7.24K | ﹤0.01% |
+482
| New | +$7.24K |
|
1537
Precigen
PGEN
$1.35B
| $7.09K | ﹤0.01% |
9,759
-647
| -6% | -$470 |
|
|
CMPS
1538
Compass Pathways
CMPS
$476M
| $6.76K | ﹤0.01% |
+1,694
| New | +$6.76K |
|
1539
MacroGenics
MGNX
$136M
| $6.75K | ﹤0.01% |
2,091
-178
| -8% | -$575 |
|
1540
dLocal
DLO
$3.82B
| $6.49K | ﹤0.01% |
576
-91
| -14% | -$1.03K |
|
|
INZY
1541
DELISTED
Inozyme Pharma
INZY
| $6.25K | ﹤0.01% |
+2,141
| New | +$6.25K |
|
1542
LendingClub
LC
$1.89B
| $6.2K | ﹤0.01% |
383
-78
| -17% | -$1.26K |
|
1543
Mersana Therapeutics
MRSN
$34.7M
| $6.18K | ﹤0.01% |
+165
| New | +$6.18K |
|
1544
Acrivon Therapeutics
ACRV
$42.8M
| $6.15K | ﹤0.01% |
+1,038
| New | +$6.15K |
|
1545
Fate Therapeutics
FATE
$113M
| $6.11K | ﹤0.01% |
+3,795
| New | +$6.11K |
|
|
EQC
1546
DELISTED
Equity Commonwealth
EQC
| $6.11K | ﹤0.01% |
3,490
-675
| -16% | -$1.18K |
|
1547
Lyell Immunopharma
LYEL
$231M
| $6.05K | ﹤0.01% |
465
+2
| +0.4% | +$26 |
|
1548
Tevogen Bio Holdings
TVGN
$174M
| $6.01K | ﹤0.01% |
+5,833
| New | +$6.01K |
|
|
AMRN
1549
Amarin Corp
AMRN
$315M
| $5.98K | ﹤0.01% |
667
-57
| -8% | -$511 |
|
1550
Alector
ALEC
$306M
| $5.81K | ﹤0.01% |
3,263
-257
| -7% | -$457 |
|